Chen Hong-Yu, Wang Qian, Xu Qiu-Hong, Yan Li, Gao Xue-Feng, Lu Yan-Hong, Wang Li
Department of Gynecology and Obstetrics, Heilongjiang Provincial Hospital, Harbin 150036, China.
School of Computer Science and Technology, Harbin University of Science and Technology, Harbin 150080, China.
Biomed Res Int. 2016;2016:9125238. doi: 10.1155/2016/9125238. Epub 2016 Nov 16.
. Despite the great achievements in the treatment of advanced-stage ovarian cancer, it is still a severe condition with an unfavorable 5-year survival rate. Statins have been suggested to reduce the risk of several cancers beyond their cholesterol-lowing effects. However, the prognostic significance of statins in patients with advanced-stage ovarian cancer remains controversial. . A retrospective study was performed to evaluate the association between statin intake and overall survival (OS) among patients with advanced-stage ovarian cancer. Patients who underwent cytoreductive surgery followed by courses of intravenous chemotherapy were matched through a propensity score analysis. . A total of 60 propensity-matched patients were included. Women in statin group showed a similar OS than the nonstatin counterparts ( = 0.966), whereas residual tumor was significantly associated with better OS ( = 0.013) and was an independent factor that associated with OS ( = 0.002, hazard ratio = 5.460, and 95% confidence interval: 1.894 to 15.742) in multivariable analysis. . Our results suggested that statin usage was not associated with improved OS in patients with advanced-stage ovarian cancer undergoing surgery and chemotherapy. Considering the retrospective nature and the relative small sample size of the study, further prospective studies and random control trials are needed.
尽管晚期卵巢癌的治疗取得了巨大成就，但它仍然是一种严重的疾病，5年生存率不容乐观。他汀类药物已被认为除了具有降低胆固醇的作用外，还能降低几种癌症的风险。然而，他汀类药物在晚期卵巢癌患者中的预后意义仍存在争议。 进行了一项回顾性研究，以评估晚期卵巢癌患者服用他汀类药物与总生存期（OS）之间的关联。通过倾向评分分析对接受细胞减灭术并随后接受静脉化疗疗程的患者进行匹配。 总共纳入了60例倾向匹配的患者。他汀类药物组的女性患者与未服用他汀类药物的患者相比，总生存期相似（P = 0.966），而残留肿瘤与更好的总生存期显著相关（P = 0.013），并且在多变量分析中是与总生存期相关的独立因素（P = 0.002，风险比= 5.460，95%置信区间：1.894至15.742）。 我们的结果表明，对于接受手术和化疗的晚期卵巢癌患者，使用他汀类药物与总生存期的改善无关。考虑到该研究的回顾性性质和相对较小的样本量，需要进一步的前瞻性研究和随机对照试验。
